Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

SAGE forges agreement with the International Headache Society

SAGE, the world's leading independent academic and professional publisher is delighted to announce a new agreement with the International Headache Society (IHS) to publish their official journal, Cephalalgia.

2 Sep 2009

Rapid progression of multiple sclerosis linked to smoking

Patients with multiple sclerosis who smoke appear to experience a more rapid progression of their disease, according to a report in the July issue of Archives of Neurology, one of the JAMA/Archives journals.

2 Sep 2009

T cells influence aggressive immune cells by regulating the chemical environment between cells

University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. The findings open a new avenue of research for future therapies for conditions ranging from autoimmune diseases to organ transplants to cancer.

2 Sep 2009

White matter hyperintensities could lead to permanent thinking problems

Elderly people with no memory or thinking problems are more likely to later develop thinking problems if they have a growing amount of "brain rust," or small areas of brain damage, according to a study published in the July 14, 2009, print issue of NeurologyÂ®, the medical journal of the American Academy of Neurology.

2 Sep 2009

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

While smoking cigarettes appears to significantly increase a person's risk of developing multiple sclerosis, using Swedish snuff does not, according to a study published in the September 1, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

1 Sep 2009

Mitoxantrone is highly efficient in suppressing multiple sclerosis

According to data supplied by the German Multiple Sclerosis Society's national MS register (DMSG - Deutsche Multiple Sklerose Gesellschaft), up to 10% of German MS patients have been treated with mitoxantrone in the past few years.

1 Sep 2009

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

31 Aug 2009

Vision document to guide CHA's support to health reform

The Catholic Health Association of the United States (CHA) has long been committed to a goal of health coverage for all people in the United States. CHA has not, however, endorsed any of the bills currently under consideration.

29 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

Bus tour campaign to raise the awareness of patient assistance programs

The 'Help is Here Express' bus tour will be stopping in Virginia throughout the week of August 31 - September 3 at various cities in order to help uninsured and financially-struggling Virginians access information on programs that provide prescription medicines for free or nearly free.

28 Aug 2009

Fast Forward selects IntraLinks to support its funding effort

IntraLinks®, the leading provider of critical information exchange solutions, today announced that Fast Forward™ has selected IntraLinks to help streamline the collection, distribution and tracking of information to support their funding of multiple biotechnology and pharmaceutical companies working on new Multiple Sclerosis (MS) treatments.

28 Aug 2009

Town halls: Even tempers prevail in Wisconsin, but not Phoenix

In Eau Claire, Wisconsin, Rep. Ron Kind, D-Wis, encountered something Democrats may have become unaccustomed to: "a fairly even-tempered crowd" at an "intimate" town hall meeting, Roll Call reports. Kind voted against the reform proposal in the House Ways and Means Committee, but defended current incarnations of the overhaul package during a meeting with local business owners and state National Federation of Independent Business representatives.

28 Aug 2009

American Scientific Resources to acquire the intellectual property of Disintegrator home needle destruction device

American Scientific Resources, Inc. (Pink Sheets: ASFX) (the Company), today confirmed that it has signed a letter of intent to acquire the intellectual property to the Disintegrator home needle destruction device (NDD) (U.S. Patent No. 6,384,362 Patent Application No.: 09/500,504).

27 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

Researchers find the method involved in setting up communications network of connections in the brain

In a new study, researchers at the Montreal Neurological Institute and Hospital (The Neuro), McGill University have found an important mechanism involved in setting up the vast communications network of connections in the brain.

27 Aug 2009

Important development in the treatment of multiple sclerosis

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009.

26 Aug 2009

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

SAGE forges agreement with the International Headache Society

Rapid progression of multiple sclerosis linked to smoking

T cells influence aggressive immune cells by regulating the chemical environment between cells

White matter hyperintensities could lead to permanent thinking problems

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

Mitoxantrone is highly efficient in suppressing multiple sclerosis

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Vision document to guide CHA's support to health reform

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Bus tour campaign to raise the awareness of patient assistance programs

Fast Forward selects IntraLinks to support its funding effort

Town halls: Even tempers prevail in Wisconsin, but not Phoenix

American Scientific Resources to acquire the intellectual property of Disintegrator home needle destruction device

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Researchers find the method involved in setting up communications network of connections in the brain

Important development in the treatment of multiple sclerosis

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Newsletters you may be interested in